Literature DB >> 22000577

Early results of core decompression and autologous bone marrow mononuclear cells instillation in femoral head osteonecrosis: a randomized control study.

Ramesh Kumar Sen1, Sujit Kumar Tripathy, Sameer Aggarwal, Neelam Marwaha, Ratti Ram Sharma, Niranjan Khandelwal.   

Abstract

Fifty-one osteonecrotic hips in 40 patients were randomly divided into 2 treatment groups. Patients in group A (25 hips) were treated with core decompression, and those in group B (26 hips) received autologous bone marrow mononuclear cell instillation into the core tract after core decompression. Outcome between the 2 groups were compared clinically (Harris Hip score), radiographically (x-ray and magnetic resonance imaging), and by Kaplan-Meier hip survival analysis after 12 and 24 months of surgical intervention. The clinical score and mean hip survival were significantly better in group B than in group A (P < .05). Patients with adverse prognostic features at initial presentation, that is, poor Harris Hip score, x-ray changes, edema, and/or effusion on magnetic resonance imaging had significantly better clinical outcome and hip survival in group B than in group A.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22000577     DOI: 10.1016/j.arth.2011.08.008

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  68 in total

1.  Intralesional autologous mesenchymal stem cells in management of osteonecrosis of femur: a preliminary study.

Authors:  S Rastogi; S R Sankineani; H L Nag; S Mohanty; G Shivanand; K Marimuthu; R Kumar; L Rijal
Journal:  Musculoskelet Surg       Date:  2013-07-14

2.  No differences in the efficacy among various core decompression modalities and non-operative treatment: a network meta-analysis.

Authors:  Byung-Ho Yoon; Young-Kyun Lee; Ki-Choul Kim; Yong-Chan Ha; Kyung-Hoi Koo
Journal:  Int Orthop       Date:  2018-05-31       Impact factor: 3.075

3.  Investigating clinical failure of core decompression with autologous bone marrow mononuclear cells grafting for the treatment of non-traumatic osteonecrosis of the femoral head.

Authors:  Lihua Liu; Fuqiang Gao; Wei Sun; Yunting Wang; Qingyu Zhang; Bailiang Wang; Liming Cheng; Zi-Rong Li
Journal:  Int Orthop       Date:  2018-04-13       Impact factor: 3.075

4.  A current review of core decompression in the treatment of osteonecrosis of the femoral head.

Authors:  Todd P Pierce; Julio J Jauregui; Randa K Elmallah; Carlos J Lavernia; Michael A Mont; James Nace
Journal:  Curr Rev Musculoskelet Med       Date:  2015-09

5.  CORR Insights®: Free Vascularized Fibular Grafting Improves Vascularity Compared With Core Decompression in Femoral Head Osteonecrosis: A Randomized Clinical Trial.

Authors:  Anton Plakseychuk
Journal:  Clin Orthop Relat Res       Date:  2017-06-22       Impact factor: 4.176

Review 6.  [Joint-preserving operative treatment of avascular necrosis of the femoral head].

Authors:  C Lüring; C Benignus; J Beckmann
Journal:  Orthopade       Date:  2018-09       Impact factor: 1.087

Review 7.  [Cell-based and future therapeutic strategies for femoral head necrosis].

Authors:  L Rackwitz; J C Reichert; M Haversath; U Nöth; M Jäger
Journal:  Orthopade       Date:  2018-09       Impact factor: 1.087

8.  Comparison of bone marrow mesenchymal stem cells and core decompression in treatment of osteonecrosis of the femoral head: a meta-analysis.

Authors:  Xu Li; Xian Xu; Wei Wu
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

Review 9.  Stem Cell Therapy for Osteonecrosis of the Femoral Head: Current Trends and Comprehensive Review.

Authors:  Lei Zhao; Alan David Kaye; Aaron J Kaye; Alaa Abd-Elsayed
Journal:  Curr Pain Headache Rep       Date:  2018-05-03

10.  Outcome of childhood leukaemia survivors and necrosis of the femoral head treated with autologous mesenchymal stem cells.

Authors:  T de Rojas; S Martínez-Álvarez; S Lerma-Lara; M Á Díaz; L Madero; M Ramírez
Journal:  Clin Transl Oncol       Date:  2017-09-12       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.